Genzyme 02/02/2010 : Cerezyme Shipment Update

Vous trouverez des articles traitant du même sujet dans la catégorie "A propos des traitements et prise en charge".

Liens utiles à la fin des catégories.
Ghislaine SURREL

maladies-lysosomales-subscribe@yahoogroupes.fr

Cerezyme Shipment Update (2/10/10)

Posted: 10 Feb 2010 02:58 PM PST

We would like to provide an update to the Gaucher community about the status of shipments of Cerezyme^®. We are planning to restart shipping Cerezyme globally on Thursday, February 11th. Local Genzyme staff will work to keep physicians updated on the status of shipments and we encourage patients to contact their local Genzyme representative or their physician about resuming infusions and the timing of their next infusions. Patients in the United States may also contact their Case Manager for additional information.

Please know that we are making every effort to minimize disruptions caused by our current circumstances. However, we expect that intermittent delays in shipping will continue to occur until we have been able to rebuild global inventory of Cerezyme. Such delays are expected mainly during the first half of 2010 as we expect supply to smooth out over the course of the year. We will do our best to keep you informed regarding any additional shipping delays. Once again, we would like to apologize for the inconvenience and uncertainty of this shipment delay.

In addition, we have received a number of questions from the community that we would like to answer here.

This posting contains forward looking statements regarding Genzyme’s future business plans and strategies, including its estimates of: when it will ship Cerezyme® (imiglucerase for injection); how much of the anticipated demand those shipments will satisfy; when it will be able to meet full demand for the product; whether intermittent delays in shipping the product will continue to occur and for how long; and when it will be in a position to provide additional information. These forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those forecasted. These risks and uncertainties include: that manufacturing and production of Cerezyme does not continue as planned due to any reason, including bacterial or viral contamination, mechanical failures, cell growth at lower than expected levels, and fill finish and regulatory issues; that release of the product is delayed, is unsuccessful or is inefficient; that Genzyme has not forecasted anticipated product demand accurately; that the period of shortage and dose conservation for Cerezyme is extended; that Genzyme continues to experience intermittent delays in shipping of Cerezyme; and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in Genzyme’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2009. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this posting. These statements speak only as of the date of this posting, and Genzyme undertakes no obligation to update or revise these statements.

---